[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Scynexis Inc (SCYX)

Scynexis Inc (SCYX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 27,245
  • Shares Outstanding, K 5,583
  • Annual Sales, $ 20,600 K
  • Annual Income, $ -8,610 K
  • EBIT $ -16 M
  • EBITDA $ -16 M
  • 60-Month Beta 1.05
  • Price/Sales 1.27
  • Price/Cash Flow N/A
  • Price/Book 0.63

Options Overview Details

View History
  • Implied Volatility 433.35% (+207.91%)
  • Historical Volatility 69.79%
  • IV Percentile 85%
  • IV Rank 47.84%
  • IV High 861.62% on 07/15/25
  • IV Low 40.63% on 03/17/26
  • Expected Move (DTE 13) 0.43 (9.14%)
  • Put/Call Vol Ratio 999.99
  • Today's Volume 1
  • Volume Avg (30-Day) 92
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 3,823
  • Open Int (30-Day) 4,176
  • Expected Range 4.23 to 5.08

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.40
  • Number of Estimates 1
  • High Estimate $-0.40
  • Low Estimate $-0.40
  • Prior Year $-1.12
  • Growth Rate Est. (year over year) +64.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.58 +2.18%
on 06/05/26
8.00 -41.48%
on 05/06/26
-2.86 (-37.96%)
since 05/05/26
3-Month
4.58 +2.18%
on 06/05/26
9.12 -48.68%
on 04/16/26
-1.66 (-26.18%)
since 03/05/26
52-Week
4.52 +3.54%
on 11/17/25
10.48 -55.34%
on 09/12/25
-2.41 (-33.95%)
since 06/05/25

Most Recent Stories

More News
SCYNEXIS Announces One-for-Eight Reverse Stock Split

JERSEY CITY, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS”), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare...

SCYX : 4.71 (-3.48%)
Scynexis: Q1 Earnings Snapshot

Scynexis: Q1 Earnings Snapshot

SCYX : 4.71 (-3.48%)
SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update

Completed transformative acquisition of PXL-770, (now SCY-770), an innovative, highly selective, direct AMPK activator for the treatment of autosomal dominant polycystic kidney disease (ADPKD) A Phase...

SCYX : 4.71 (-3.48%)
SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

JERSEY CITY, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX) (“SCYNEXIS” or the “Company”), a biotechnology company focused on developing innovative new therapies to address...

SCYX : 4.71 (-3.48%)
SCYNEXIS Announces $40.0 Million Private Placement

JERSEY CITY, N.J., March 31, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:  SCYX ) (“SCYNEXIS” or the “Company”), a biotechnology company focused on developing innovative new therapies...

SCYX : 4.71 (-3.48%)
SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

PXL-770 (now SCY-770) is a clinical stage, well-characterized oral therapy designed to address the underlying drivers of ADPKD by reducing cyst growth and disease progression A Phase 2 proof-of-concept...

SCYX : 4.71 (-3.48%)
Scynexis: Q4 Earnings Snapshot

Scynexis: Q4 Earnings Snapshot

SCYX : 4.71 (-3.48%)
SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update

SCYNEXIS received a one-time non-refundable payment in Q4 2025 totalling $24.8 million from GSK SCYNEXIS announced dosing of the first patient using the intravenous (IV) formulation of SCY-247 in a...

SCYX : 4.71 (-3.48%)
SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247

JERSEY CITY, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:  SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant...

SCYX : 4.71 (-3.48%)
SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)

JERSEY CITY, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant...

SCYX : 4.71 (-3.48%)

Business Summary

SCYNEXIS, Inc. is a pharmaceutical company. It is engaged in the discovery, development, and commercialization of anti-infectives to address unmet therapeutic needs. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening...

See More

Key Turning Points

3rd Resistance Point 5.58
2nd Resistance Point 5.36
1st Resistance Point 5.12
Last Price 4.71
1st Support Level 4.66
2nd Support Level 4.44
3rd Support Level 4.20

See More

52-Week High 10.48
Fibonacci 61.8% 8.20
Fibonacci 50% 7.50
Fibonacci 38.2% 6.80
Last Price 4.71
52-Week Low 4.52

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.